BridgeMD
New treatment option for Hamstring Muscle Strain
Official title BPC 157 for Acute Hamstring Muscle Strain Repair
ClinicalTrials.gov ID: NCT07437547
What this study is testing
What is Pentadecapeptide BPC 157?
Pentadecapeptide BPC 157 is an investigational medicine, given as an once-daily injection under the skin, being studied as a potential treatment for hamstring muscle strain.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45
You may be able to join if
- Age 18 to 45 years.
- Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening.
- MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion.
- Pre-injury physical activity \>= 3 sessions/week or participation in organized recreational sport.
- Willingness to follow the standardized rehabilitation protocol and attend all study visits.
You likely can't join if
- Grade III hamstring tear, tendon avulsion, or injury requiring surgical management.
- Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment.
- Prior hamstring strain on the index limb within the past 6 months.
- Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days...
- Known bleeding disorder or current therapeutic anticoagulation.
- Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk.
See the full eligibility criteria
- Age 18 to 45 years.
- Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening.
- MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion.
- Pre-injury physical activity \>= 3 sessions/week or participation in organized recreational sport.
- Willingness to follow the standardized rehabilitation protocol and attend all study visits.
- For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose.
- Grade III hamstring tear, tendon avulsion, or injury requiring surgical management.
- Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment.
- Prior hamstring strain on the index limb within the past 6 months.
- Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days prior to screening.
- Known bleeding disorder or current therapeutic anticoagulation.
- Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk.
- Known allergy or hypersensitivity to components of the investigational product or placebo.
- Pregnant or breastfeeding.
- Current participation in another treatment clinical study or participation within 30 days prior to screening.
- Currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority
The study team makes the final eligibility decision.
Where it's taking place
- Shenzhen, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenzhen, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.